RecruitingNCT06893328

A Real World Study About PMN

PMNTRWS: A Non-interventional Study on Treatment and Therapeutic Efficacy in Chinese Patients With Primary Membranous Nephropathy (PMNTRWS)"

Sponsor

Wei Chen

Enrollment

200 participants

Start Date

Nov 11, 2024

Study Type

OBSERVATIONAL

Conditions

Primary Membranous Nephropathy

Summary

The investigators designed a randomized, controlled, multicenter clinical study to compare the efficacy and safety of rituximab combined with hormones versus rituximab monotherapy in the treatment of primary membranous nephropathy. At the same time, the investigators conducted a real-world study on patients who did not meet the inclusion and exclusion criteria or were unwilling to enter the RCT cohort, to further observe the trial results in a broader population.

Eligibility

Min Age: 18 Years

Inclusion Criteria2

\. Diagnosed as primary membranous nephropathy (PMN) by renal biopsy; 2. Aged over 18 years; 3. An average 24-hour urine protein ≥ 3.5g twice a week after treatment with ACE inhibitors or ARBs for at least 3 months.
\-

Exclusion Criteria4

With secondary membranous nephropathy (such as hepatitis B and C, systemic lupus erythematosus, drug therapy, malignant tumors and other secondary causes);
Active infection, such as active hepatitis B or hepatitis C, tuberculosis (evidence of active tuberculosis infection within 1 year), or human immunodeficiency virus HIV infection (positive for anti-HIV antibodies), etc.
A history of immunodeficiency, including other acquired or congenital immunodeficiency diseases, or organ transplantation.
\-

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.